Cancer immunotherapy has its extensive utilization in the treatment of blood cancer, prostate cancer, breast cancer, colorectal cancer and lung cancer. With the deteriorating lifestyles of individuals, the incidence of cancer and cancer patients is snowballing at a rapid rate.
According to the MarkNtel Advisors’ research report, the CAGR of “Global Cancer Immunotherapy Market Analysis, 2020”, is expected to be around 13% during 2020-25.
Checkpoint Inhibitors Dominating the Cancer Immunotherapy Market
Owing to the high adoption in the treatment of cancers, the market of checkpoint inhibitors is soaring at considerable pace. Checkpoint inhibitors grabbed the largest market share in 2019 and is anticipated to grow during 2020-25. The companies operating in the checkpoint inhibitors are focused on develop new technologies to gain the competitive advantage.
In 2019, APAC region grabbed the considerable market share on account of rising government investments and snowballing cancer incidence in the region.
The lung cancer immunotherapy grabbed the largest market share in 2019 due to the growing number of individuals getting addicted to smoking and alcoholism. Another major reason contributing to the growth of cancer immunotherapy is alarming levels of pollution in urban cities.
According to the MarkNtel Advisors the major leading players are AstraZeneca plc, Amgen, Novartis AG, Merck & Co., Inc., Celgene Corporation, Bristol-Myers, Pfizer, Bayer, F. Hoffmann-La-Roche, Squibb among others. Genetech subsidiary of Roche was approved for the usage of atezolizumab, a monoclonal antibody for the treatment of non-small lung cell in in 2016.
Top five cancer drugs are Avastin, Nivolumab, Revlimid, Rituxan and Xtandi. A single drug, Bristol-Myers Squibb's Yervoy has earned revenues of about USD 960 million in 2013 and it is expected to reach USD 1,775.2 million in 2020.
Key Questions Answered in the Market Research Report
Market Outlook, Segmentation and Statistics
Frequently Asked Questions
Q. What is the historical year, base year and forecast year considered in the research report on Global Cancer Immunotherapy Market?
A. The historical data has been provided since 2015, while the base year is 2019 and the data is forecasted up to 2025
Q. What are the units or denomination for measuring market value in the report?
A. The market size/industry size or the market value is measured in terms of USD Million.
Q. What would be the CAGR of the Global Cancer Immunotherapy Market during 2020 to 2025?
A. The market size of Global Cancer Immunotherapy Market would register a CAGR of 13% during 2020-25.
Q. Does the report scope cover region wise market statistics also?
A. Yes, the scope of the report encompasses detailed region wise statistics such as market size, market segmentation based on various subcategories.
Q. Which of the regions would be a bright spot for Global Cancer Immunotherapy Market during 2020-2025?
A. Asia-Pacific region grabbed the considerable market share on account of rising government investments and snowballing cancer incidence in the region.
Q. Which of the product type would be a bright spot for Global Cancer Immunotherapy Market during 2020-2025?
A. Owing to the high adoption in the treatment of cancers, the market of Checkpoint Inhibitors Dominating the Cancer Immunotherapy Market. Checkpoint inhibitors grabbed the largest market share in 2019 and is anticipated to grow during 2020-25.
Q. Which of the cancer immunotherapy would be a bright spot for Global Cancer Immunotherapy Market during 2020-2025?
A. The lung cancer immunotherapy grabbed the largest market share due to the growing number of individuals getting addicted to smoking and alcoholism. Another major reason contributing to the growth of cancer immunotherapy is alarming levels of pollution in urban cities.
Q. Who are the key players or major competitors in Global Cancer Immunotherapy Market?
A. AstraZeneca plc, Amgen, Novartis AG, Merck & Co., Inc., Celgene Corporation, Bristol-Myers, Pfizer, Bayer, F. Hoffmann-La-Roche, Squibb. are few of the leading players with majority market share in Global Cancer Immunotherapy Market.
Q. Does the report scope cover Cancer Immunotherapy type wise market statistics also?
A. Yes, the scope of the report encompasses detailed Cancer Immunotherapy type wise statistics such as market size, market segmentation based on various subcategories.
